"We are cautiously optimistic about what we will achieve in 2024," CEO Albert Bourla said during a call with analysts. Shares ...
Thrombosis caused by the AstraZeneca vaccine and myocarditis caused by the messenger-RNA vaccines of BioNTech and Pfizer have ...
In an exclusive report by the Epoch Times, U.S. Centers for Disease Control and Prevention (CDC) officials found evidence ...
Pfizer beat first-quarter profit estimates on Wednesday, benefiting from cost cuts and strong sales for its pneumonia and ...
GNW-Adhoc: Idorsia publishes an invitation to a bondholder meeting23. Apr. · dpa-AFX GNW-Adhoc: Idorsia publishes a Financial Status required for an upcoming bondholder meeting17. Apr. · dpa-AFX ...
Pfizer (PFE) beats first-quarter estimates for earnings and sales. It raises 2024 earnings guidance while retaining revenue ...
Investors have also been tracking the performance of the company's new RSV vaccine, which has been trailing a rival shot from ...
Pfizer lifted its annual earnings forecast on Wednesday and reported a first-quarter profit above Wall Street estimates, ...
Comirnaty vaccine marketed with BIoNTech (NASDAQ:BNTX) added $354M in revenue with a ~88% drop while COVID-19 pill Paxlovid generated $2.0B indicating a ~50% YoY drop. However, the company’s non-COVID ...
The continent – in dire need of its own production capabilities – could once again be at the back of the vaccine queue in the ...
Revenue from Comirnaty, for which it partners with Germany's BioNTech, continues to perform consistently with its ...
13h
With the ongoing global efforts to combat the COVID-19 pandemic, vaccination has emerged as a critical tool in safeguarding ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results